Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321022 | 0.88 | TSHR (0.33) | ACHETSHR | |
| SCHEMBL23016861 | 0.85 | P2RX7 (0.36) | ACHETSHRTP53HTTALDH1A1 | |
| SCHEMBL6314598 | 0.84 | TRPA1 (0.34) | TSHR | |
| SCHEMBL3882276 | 0.83 | ACHE (0.39) | ACHETSHRELANEMAPTHTT | |
| SCHEMBL7063606 | 0.82 | MCHR1 (0.36) | ALDH1A1 | |
| SCHEMBL6911940 | 0.78 | CYP2C9 (0.36) | ACHETSHRTP53HTTALDH1A1 | |
| SCHEMBL7468495 | 0.78 | GABRA1 (0.35) | TP53MAPT | |
| SCHEMBL20627378 | 0.78 | ALDH1A1 (0.33) | TSHRTP53ALDH1A1 | |
| SCHEMBL5320697 | 0.78 | TP53 (0.30) | TP53 | |
| SCHEMBL6914519 | 0.76 | ALDH1A1 (0.39) | TSHRHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838019-B2 | Phosphorescent material and electroluminescent device using thereof | RITEK CORPORATION (TW) | 2005-01-04 | — | — | US | claimed |
| US-20030102800-A1 | Phosphorescent material | RITEK CORPORATION (TW) | 2003-06-05 | — | — | US | claimed |
| CN-1288222-C | Phosphorescent light-emitting material | LAIDE SCIENCE & TECHNOLOGY CO (CN) | 2006-12-06 | — | — | CN | disclosed |
| US-6838019-B2 | Phosphorescent material and electroluminescent device using thereof | RITEK CORPORATION (TW) | 2005-01-04 | — | — | US | disclosed |
| CN-1464027-A | Phosphorescent light-emitting material | LAIDE SCIENCE & TECHNOLOGY CO (CN) | 2003-12-31 | — | — | CN | disclosed |
| US-20030102800-A1 | Phosphorescent material | RITEK CORPORATION (TW) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030102800-A1 | Phosphorescent material | PKD1, RPS6KA1, RPS6KA6 | ACHE 4774/4885TSHR 3823/4885TP53 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.